Gemcitabine: Once-weekly schedule active and better tolerated than twice-weekly schedule

Anti-Cancer Drugs

Volumn 7, Issue 3, 1996, Pages 351-357

  Martin, Christophe ^a,c   Lund, Birthe ^a   Anderson, Heather ^a   Thatcher, Nicholas ^b  

^a ELI LILLY AND COMPANY   (United States)

^b University of Copenhagen   (Denmark)

^c WYTHENSHAWE HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; Efficacy; Gemcitabine; NSCLC; Safety

Indexed keywords

GEMCITABINE;

ARTICLE; CLINICAL TRIAL; EDEMA; HUMAN; INFLUENZA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; META ANALYSIS; NAUSEA; NEPHROTOXICITY; PRIORITY JOURNAL; THROMBOCYTOPENIA; VOMITING;

EID: 0029973099     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199605000-00017     Document Type: Article

References (28)

1. Grindey GG, Bocler GB, Hertel LH, et al. Antitumor activity of 2′,2′-difluorodeoxycitidine (LY188011). Proc Am Ass Cancer Res 1986; 27: 296 (abstr 1775).
2. Chubb S, Heinemann V, Novotny L, et al. Metabolism and action of 2′,2′-difluorodeoxycytidine (dFdC) in human leukemia cell. Proc Am Ass Cancer Res 1987; 28: 324 (abstr 1282).
3. Bhalla K, Maclaughlin W, Cole J, et al. Continuously administered 2′,2′-difluorodeoxycytidine (dFdC) and deoxycytidine (dCyd): a potentially selective cytotoxic regimen toward human leukemic myeloid progenitors in culture. Proc Am Ass Cancer Fes 1988; 28: 348 (abstr 1385).
4. Fujita F, Fijita M, Inaba H, et al. Effects of a new anticancer agent, LY188011 on human cancer xenografts in nude mice. In: Proc 48th Annual Meeting of the Japanese Cancer Association, Nagoya, Japan. October 23-25, 1989 (abstr 1938).
5. Tanayanagi C, Takauji R, Ueda T, et al. Action mechanism of difluorodeoxycitidine (dFdC), a new ara-C derivative. Acta Hematol Jon 1990; 53: 76 (abstr 132).
6. Bouffard DY, Momparler LF, Momparler RL. Comparison of antineoplastic activity of cytosine arabinoside and 2′,2′-difluorodeoxycytidine on human myelod, T-cell and B-cell leukemic cells. Eur J Pharmacol 1990; 183: 161, 1990 (abstr 32).
7. Plunkett W, Chubb S, Nowak B, et al. Increased cytotoxicity and therapeutic activity of 2′,2′-difluorodeoxycytidine over cytosine arabinoside (ara-C) in L1210 leukemia. Proc Am Ass Cancer Res 1988; 29: 352 (abstr 1402).
8. O'Rourke, Brown T, Havlin, et al. Phase I clinical trial of gemcitabine given as an intravenous bolus on five consecutive days. Eur J Cancer 1994; 30: 417-8.
9. Poplin E, Redman B, Flaherty L, et al. Difluorodeoxycytidine (dFdC): a phase I study. Proc Am Soc Oncol 1989; 30: 282.
10. Gruewald R, Kantarjian H, Keating M, et al. Pharmacologically divected design of the dose rate and schedule of 2′,2′-difluorodeoxycytidine (gemcitabine) administration in leukemia. Cancer Res 1990; 50: 6823-6.
11. Abbruzzese JL, Grunewald R, Weeks EA, et al. A phase I clinical, plasma and cellular pharmacology study of gemcitabine. J Clin Oncol 1991; 9: 491-8.
12. Anderson H, Lund B, Bach F, et al. Single-agent activity of weekly gemcitabine in advanced non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1821-6.
13. Gatzemeier U, Shepherd FA, Le Chevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 1996; 32: 243-8.
14. Kaye SB. Gemcitabine current status of phase I and II trials. J Clin Oncol 1994; 12: 1527-31.
15. Abratt RP, Werner RB, Falkson G, et al. Efficacy and safety of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994; 12: 1535-40.
16. Carmichael J. Fink U, Russell RCG, et al. Phase II study in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-5.
17. Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2′,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Dntgs 1994; 12: 29-34.
18. Lund B, Hansen OP, Theilade K, et al. Phase II study of gemcitabine (2′,2′-difluorodeoxycitidine) in previously treated ovarian cancer. J Natl Cancer Inst 1994; 86: 1530-3.
19. Carmichael J, Possinger K, Phillip P, et al. Advanced breast cancer: a phase II trial with gemcitabine. J Clin Oncol 1995; 13: 2731-6-
20. Cormier Y, Eisenhauer E, Muldal A, et al. Gemcitabine is an active new agent in previously un-treated extensive small cell lung cancer. A study of the National Cancer Institute of Canada Clinical Treatment Group. Ann Oncol 1994; 5: 283-5.
21. Pollera CF, Ceribelli A, Crecco M, Calabresi F. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol 1994; 5: 182-4.
22. Catimel G, Vermerken JB, Clavel M, et al. A phase II study of gemcitabine (LY188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 543-7.
23. De Mulder PHM, Weissbach L, Jakse G, et al. Gemcitabine: a phase II study in patients with advanced renal cancer. Cancer Chemother Pharmacol 1996; 37: 491-5.
24. Merterns WC, Eisenhauer EA, Moore M, et al. Gemci-tabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials group. Ann Oncol 1994; 4: 331-2.
25. Walling J. Chemotherapy of advanced non-small cell lung cancer. Respir Med 1994; 8: 649-657.
26. Lund B, Ryberg M, Meidahl Peterson P, et al. Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously treated patients with non-small cell lung cancer. Ann Oncol 1994; 5: 852-3.
27. Abbruzzese JL, Pazdur R, Ajani J, et al. A phase II trial of gemcitabine in patients with advanced colorectal cancer. Proc Am Soc Clin Oncol 1991; 10: 456.
28. Christman K, Kelsen D, Saltz L, et al. Phase II trial of gemcitabine in patients with advanced gastric cancer. Cancer 1994; 73: 5-7.